Vericel VCEL Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Product sales, net by Product | ||||||
| Biopsy kits | $2.62M+23.3% | $2.61M+24.6% | $2.46M+17.2% | $2.27M+9.1% | $2.12M+0.1% | |
| Epicel | $37.99M+22.8% | $32.07M-12.4% | $29.97M-21.9% | $31.78M-5.4% | $30.92M-12.7% | |
| M A C I Implants and kits | $249.61M+22.7% | $239.51M+21.4% | $223.75M+20.5% | $212.75M+19.1% | $203.42M+19.1% | |
| MACI implants, kits, and instruments | $189.18M+29.8% | $179.5M+27.2% | $163.92M+28.8% | $154.46M+30.7% | $145.74M+32.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Vericel break its business down?
- Vericel (VCEL) reports product sales, net by product across 4 parts — Biopsy kits, Epicel, M A C I Implants and kits and MACI implants, kits, and instruments. Each is extracted from the segment footnotes and tracked over time.
- Where does Vericel's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Vericel's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.